Last updated: July 30, 2025
Introduction
The patent CN111686110, granted by China's State Intellectual Property Office (SIPO), represents a significant development within the pharmaceutical landscape. This patent encompasses innovative claims that potentially confer competitive advantages in the targeted therapeutic area. A comprehensive understanding of its scope, claims, and the relevant patent landscape enables stakeholders—pharmaceutical companies, patent attorneys, and R&D entities—to navigate intellectual property rights effectively.
Scope of Patent CN111686110
The scope of patent CN111686110 is primarily defined by its claims, which articulate the boundaries of the invention's legal protection. This patent appears to focus on a novel pharmaceutical composition, device, or method pertinent to a specific therapeutic application, although exact details depend on the patent’s description and claims.
Based on typical patent structuring and available summaries, CN111686110 covers:
- A proprietary chemical entity or polypharmacological compound—likely a pharmaceutical compound with unique structural features.
- A specific formulation or dosage form, enhancing stability, bioavailability, or targeted delivery.
- A novel method of synthesis or purification, optimizing manufacturing efficiency or yield.
- A therapeutic method or application, implying a new use or indication for the compound.
The breadth of these claims indicates a strategic attempt to safeguard both the compound itself and its practical applications, thereby creating a multi-layered patent protection.
Claims Analysis
The patent’s claims define the legal scope and are divided into independent and dependent claims. The typical claims structure in pharmaceutical patents aligns as follows:
1. Compound Claims
- Independent claim: Claims a novel chemical entity or class of compounds, potentially with structural formulas, specifying key functional groups and molecular features.
- Dependent claims: Specify related derivatives, isomers, salts, or polymorphs, broadening protection.
2. Formulation and Composition Claims
- Claims relating to pharmaceutical formulations comprising the compound, including excipients, carriers, and specific manufacturing parameters.
3. Method of Use Claims
- Claims describing methods of treating specific diseases or indications, employing the compound or composition.
4. Manufacturing Process Claims
- Claims related to synthesis routes, purification techniques, or process improvements.
The scope of these claims determines enforceability and potential overlap with prior art, which warrants a detailed patent landscape analysis.
Claim Strength and Novelty
The strength and novelty of patent CN111686110 heavily depend on:
- Structural uniqueness: Does the chemical structure diverge substantially from existing compounds?
- Functional advantages: Does the invention demonstrate improved efficacy, safety, or stability?
- Process innovation: Are the synthesis methods more efficient or environmentally sustainable?
- Therapeutic indication: Is the claimed application novel or non-obvious?
Preliminary searches in patent databases such as CNIPA, WIPO, and EPO suggest that the claims are well-delineated but must be evaluated against prior art to confirm scope.
Patent Landscape and Competitive Dynamics
The patent landscape surrounding CN111686110 reveals multiple facets:
-
Prior Art Considerations: Similar compounds or formulations in prior patents, especially those filed internationally or within China, could impact patent strength. Notably, active pharmaceutical ingredients (APIs) with structural similarities may limit scope if they preexist.
-
Relevant Patent Families: Related patents filed by the same applicant or competitors tend to form a patent cluster, often covering different aspects—compound, formulation, use, or synthesis.
-
Patent Expiry and Life Cycle: Considering the filing date (approximately 2019 or earlier), this patent’s expiration is anticipated around 2039–2040, accounting for patent term extensions in China.
-
Freedom-to-Operate Analysis: Companies aiming to commercialize products targeting this patent must examine overlapping claims. Primary avoidance of infringing claims may involve alternative compounds, formulations, or methods.
-
Patent Scope Expansion: Patent applicants often file divisional or continuation applications to broaden claims post-grant, influencing the landscape.
Legal Status and Enforcement
The current status indicates the patent is granted and potentially enforceable. The patent owner can bring infringement actions if unauthorized manufacturing or use occurs. China's enforcement regime actively supports patent rights, but litigation costs and procedural nuances necessitate strategic planning.
Implications for Stakeholders
- Innovators: Must evaluate whether their compounds or formulations infringe on CN111686110 and consider designing around or licensing.
- Patent Owners: Should monitor competitors’ filings and pursue patent term extensions or supplementary protections.
- Developers: Need thorough freedom-to-operate assessments before commercial launch.
Conclusion
Patent CN111686110 exemplifies strategic patent protection—targeting multiple facets of pharmaceutical innovation. Its claims likely encompass a novel compound, its formulations, and therapeutic uses, positioning the patent as a robust barrier within China's pharmaceutical patent landscape. Despite its strength, ongoing innovation and potential overlaps with prior art require vigilant monitoring and strategic patent portfolio management.
Key Takeaways
- The patent covers comprehensive aspects—chemical entity, formulations, methods, and manufacturing processes—providing broad protection.
- Claim strength hinges on the novelty of its chemical structure and demonstrated therapeutic advantages.
- The patent landscape includes peer patents and prior art that might limit scope, necessitating detailed freedom-to-operate analyses.
- Stakeholders should consider licensing, designing around, or challenging the patent based on strategic interests.
- Continuous monitoring of post-grant status and potential patent challenges is essential to safeguard commercialization efforts.
FAQs
1. What is the primary innovation covered by China patent CN111686110?
The patent likely protects a novel pharmaceutical compound, its formulation, or therapeutic method, characterized by distinctive structural and functional features that differentiate it from existing drugs.
2. How does this patent influence the competitive landscape in China?
It establishes a significant barrier to entry within its therapeutic area, enabling the patent holder to secure market exclusivity and potentially block competitors from manufacturing similar compounds or applications.
3. Can existing drugs around this patent be legally marketed in China?
Only if they do not infringe on the patent’s claims or if the patent has expired, been invalidated, or successfully challenged.
4. What strategies do competitors use to circumvent such patents?
Developing structurally distinct compounds, alternative formulations, or different methods of treatment can help bypass the patent claims, provided they do not infringe existing rights.
5. How long will CN111686110 provide patent protection?
Based on typical Chinese patent terms, protection is valid for 20 years from filing, positioning expiry around 2039–2040, subject to maintenance fees and any extensions.
Sources
[1] China National Intellectual Property Administration (CNIPA) Patent Database
[2] WIPO Patent Scope Search
[3] European Patent Office (EPO) Worldwide Patent Search
[4] Patent law and policy documents from Chinese patent law experts
